Press release
Scabies Market Set to Witness Significant Growth by 2025-2034
IntroductionScabies is a highly contagious skin condition caused by the mite Sarcoptes scabiei, leading to intense itching, rashes, and secondary bacterial infections. It remains a significant public health issue worldwide, particularly in regions with crowded living conditions, limited access to healthcare, and inadequate sanitation. According to the WHO, scabies affects over 200 million people at any given time, underscoring its global health burden.
The market for scabies treatment is expanding as governments, NGOs, and pharmaceutical companies strengthen their efforts in awareness, diagnosis, and treatment accessibility. Driven by increased drug availability, public health programs, and research into resistance management, the global scabies market is expected to grow steadily between 2024 and 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71436
Market Overview
• 2024 Market Size: ~USD 1.2 billion
• 2034 Forecast: ~USD 2.0 billion
• CAGR (2025-2034): ~5.2%
• Key Growth Drivers: Rising global prevalence, expanding mass drug administration programs, increasing generic drug availability, and greater emphasis on dermatology awareness.
• Challenges: Limited awareness in low-resource regions, growing resistance to standard treatments like permethrin and ivermectin, and difficulties in reaching rural populations.
• Leading Players: GlaxoSmithKline, Pfizer, Novartis, Sun Pharmaceutical, Teva Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Johnson & Johnson, Cipla, and Sanofi.
The scabies market is shaped by strong demand for low-cost generics, while innovation focuses on resistance management and improved distribution strategies.
Segmentation Analysis
By Treatment Type
• Topical Therapies
o Permethrin cream (first-line treatment)
o Benzyl benzoate lotion
o Sulfur ointments
o Lindane lotion (restricted in some regions due to toxicity)
• Oral Therapies
o Ivermectin (used in mass drug administration campaigns)
• Adjunctive Therapies
o Antihistamines for itch relief
o Antibiotics for secondary bacterial infections
By Distribution Channel
• Hospitals
• Retail pharmacies
• Online pharmacies
• Public health programs
By End Use
• Adults
• Children
• Institutional populations (schools, prisons, elderly care homes)
Summary:
Topical therapies dominate the market, but oral ivermectin is increasingly used in large-scale treatment campaigns, particularly in endemic regions. Online pharmacies and public health programs are expanding accessibility.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71436/scabies-market
Regional Analysis
• North America: Accounts for steady market demand, with outbreaks in institutional settings such as nursing homes and schools driving treatment usage.
• Europe: Growing prevalence in migrant and refugee populations, coupled with public health initiatives, supports moderate growth.
• Asia-Pacific: Expected to post the fastest CAGR, given high disease burden in India, China, and Southeast Asia, alongside increased drug accessibility and public health programs.
• Middle East & Africa: High prevalence due to limited sanitation and overcrowding; global aid programs are crucial for growth here.
• Latin America: Brazil and Mexico are leading markets, supported by government-backed campaigns and improved dermatology infrastructure.
Regional Summary:
Asia-Pacific, Africa, and Latin America bear the highest disease burden, making them the focus of mass treatment programs, while North America and Europe focus more on outbreak management in institutional populations.
Market Dynamics
Key Growth Drivers
• Rising global prevalence of scabies, particularly in low- and middle-income countries.
• Expanding mass drug administration (MDA) programs using ivermectin.
• Greater availability of affordable generics through global pharma companies.
• Increasing awareness campaigns from WHO and NGOs.
• Integration of scabies management into broader public health and dermatology initiatives.
Key Challenges
• Emerging drug resistance to permethrin and ivermectin.
• Underreporting and lack of surveillance in rural and underserved regions.
• Limited healthcare access in high-burden areas.
• Safety concerns with repeated use of some topical treatments.
Latest Trends
• Research into novel antiparasitic agents to address drug resistance.
• Expansion of teledermatology to improve diagnosis in remote areas.
• Growing role of community-based distribution programs for treatment delivery.
• Increasing focus on child and elderly populations, where scabies is most severe.
• Partnerships between pharmaceutical companies and public health agencies to strengthen global access.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71436
Competitor Analysis
Major Players
• GlaxoSmithKline (GSK) - Active in antiparasitic treatments and global health initiatives.
• Pfizer - Strong in systemic drug development and infectious disease therapies.
• Novartis - Developing antiparasitic and supportive dermatology solutions.
• Sun Pharmaceutical & Dr. Reddy's Laboratories - Providing cost-effective generics globally.
• Teva Pharmaceuticals & Mylan - Expanding reach in low- and middle-income markets.
• Johnson & Johnson - Diversified healthcare portfolio including antiparasitic agents.
• Cipla - Generics for mass treatment campaigns.
• Sanofi - Active in neglected tropical diseases and dermatology.
Summary:
The competitive landscape is driven by generics manufacturers ensuring affordability and multinational firms supporting public health programs. Drug innovation is increasingly focused on overcoming resistance challenges.
Conclusion
The global scabies market is projected to grow from USD 1.2 billion in 2024 to nearly USD 2.0 billion by 2034, at a CAGR of 5.2%. Demand is fueled by rising prevalence, greater awareness, and expanding access to treatment, particularly in high-burden regions.
Key Takeaways:
• Scabies remains a significant global public health challenge, especially in low-resource settings.
• Topical permethrin dominates, but oral ivermectin is critical for large-scale campaigns.
• Asia-Pacific and Africa are the fastest-growing regions due to high prevalence.
• Challenges include drug resistance, underreporting, and limited healthcare access.
• Future opportunities lie in novel antiparasitics, public-private partnerships, and digital health integration.
This report is also available in the following languages : Japanese (疥癬市場), Korean (옴 시장), Chinese (疥疮市场), French (Marché de la gale), German (Krätzemarkt), and Italian (Mercato della scabbia), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71436
Our More Reports:
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market
https://exactitudeconsultancy.com/reports/71602/chemotherapy-induced-peripheral-neuropathy-cipn-market
Gene Therapy in Oncology: Innovation to Commercialization, Competitive Landscape, Technological Advancements Market
https://exactitudeconsultancy.com/reports/71604/gene-therapy-in-oncology-innovation-to-commercialization-competitive-landscape-technological-advancements-market
Mycosis Fungoides (MF) Market
https://exactitudeconsultancy.com/reports/71606/mycosis-fungoides-mf-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Scabies Market Set to Witness Significant Growth by 2025-2034 here
News-ID: 4166717 • Views: …
More Releases from Exactitude Consultancy

Centronuclear Myopathy Market Projected to Grow at 7.8% CAGR
Introduction
Centronuclear myopathy (CNM) is a rare genetic neuromuscular disorder characterized by abnormal central positioning of nuclei in skeletal muscle fibers, leading to muscle weakness, hypotonia, delayed motor milestones, and in severe cases, respiratory complications. It includes subtypes such as X-linked myotubular myopathy (XLMTM), autosomal recessive CNM, and autosomal dominant CNM.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72249
Although treatment is largely supportive today, breakthroughs in gene therapies, enzyme replacement…

Choroidal Neovascularization Market to Reach USD 18.9 Billion by 2034
Choroidal neovascularization (CNV) refers to the growth of abnormal blood vessels from the choroid into the subretinal space, commonly associated with age-related macular degeneration (AMD), high myopia, ocular trauma, and inflammatory diseases. CNV is a leading cause of vision loss in working-age and elderly populations, making it a critical focus in ophthalmology.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72251
The introduction of anti-VEGF therapies, laser photocoagulation, photodynamic therapy (PDT),…

Corneal Epithelial Defect Market to Reach USD 2.5 Billion by 2034
Corneal epithelial defects (CEDs) are disruptions in the corneal epithelium, often caused by trauma, infections, contact lens misuse, refractive surgery, or underlying systemic conditions like diabetes and autoimmune disorders. Left untreated, CEDs can lead to infections, scarring, recurrent erosions, and vision loss, making early diagnosis and treatment crucial.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72253
With the increasing global burden of ocular surface diseases, rising cataract/refractive surgeries, and corneal…

Cataract Surgery Complications Market Projected to Grow at 7.5% CAGR
Introduction
Cataract surgery is the most common ophthalmic surgical procedure worldwide, with millions of procedures performed annually. While advances in surgical techniques and intraocular lens (IOL) technologies have improved outcomes, post-operative complications such as posterior capsule opacification (PCO), cystoid macular edema (CME), endophthalmitis, retinal detachment, and corneal edema remain significant clinical and economic concerns.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72247
The growing global population, increasing number of elderly patients,…
More Releases for Scabies
Scabies Treatment Market is Thriving Worldwide | Apotex, Mylan, Bayer
The Latest published market study on Global Scabies Treatment Market provides an overview of the current market dynamics in the Scabies Treatment, as well as what our survey respondents all outsourcing decision-makers predict the market will look like in 2032. The study breaks the market by revenue and volume (wherever applicable) and price history to estimate the size and trend analysis and identify gaps and opportunities. Some of the players…
Scabies Treatment Market Top Emerging Trends, Growth And Business Opportunities …
Precision Business Insights published a research report on "Scabies Treatment Market By Drug type (Sulphur Ointment, Benzyl Benzoate Lotion, Lindane Lotion, Crotamiton Cream, Permethrin Cream, Others), route of administration (Oral, Topical), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027"
Scabies is an infectious skin condition that causes itching and pimple-like rashes. The development of tiny mites called Sarcoptes scabiei in the skin causes this…
Scabies Treatment Market Growing Worldwide with New Innovations; Industry Analys …
Scabies is an infectious skin disease caused by microscopic mites known as Sarcoptes scabiei, that lives inside human skin. The mites burrows into the skin and lay eggs after staying for two to three weeks. Scabies is an itchy, rash and pimple like skin disease condition found, globally. Scabies is a highly contagious disease and can pass through simple contact with affected person. The disease is pruritic in nature. The…
Scabies Treatment Market to Observe Strong Development by 2026
Scabies is an infectious skin disease caused by microscopic mites known as Sarcoptes scabiei, that lives inside human skin. The mites burrows into the skin and lay eggs after staying for two to three weeks. Scabies is an itchy, rash and pimple like skin disease condition found, globally. Scabies is a highly contagious disease and can pass through simple contact with affected person. The disease is pruritic in nature. The…
Scabies Treatment Market Dynamics, Segments and Supply Demand 2016-2026
Scabies is an infectious skin disease caused by microscopic mites known as Sarcoptes scabiei, that lives inside human skin. The mites burrows into the skin and lay eggs after staying for two to three weeks. Scabies is an itchy, rash and pimple like skin disease condition found, globally. Scabies is a highly contagious disease and can pass through simple contact with affected person. The disease is pruritic in nature. The…
Scabies Treatment Market Analysis, Trends, Forecast, 2016-2026
Scabies is an infectious skin disease caused by microscopic mites known as Sarcoptes scabiei, that lives inside human skin. The mites burrows into the skin and lay eggs after staying for two to three weeks. Scabies is an itchy, rash and pimple like skin disease condition found, globally. Scabies is a highly contagious disease and can pass through simple contact with affected person. The disease is pruritic in nature. The…